Dermatitis, Atopic Clinical Trial
Official title:
In-Use Test With a Cosmetic Product (WO 4260) for Topical Use on the Scalp
Verified date | August 2017 |
Source | Dr. August Wolff GmbH & Co. KG Arzneimittel |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to evaluate the tolerance of the product WO 4260 by a dermatologist. Additional objectives of this clinical in-use study are to evaluate the cosmetic features and acceptance of the product by means of a questionnaire in an interview situation and by skin hydration measurements on the scalp.
Status | Completed |
Enrollment | 34 |
Est. completion date | February 27, 2017 |
Est. primary completion date | February 27, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - age: = 18 years - sex: approx. 50% male and approx. 50% female - users of hair tonic for dry scalp - dry, itchy scalp prone to atopic eczema / atopic dermatitis Exclusion Criteria: - any deviation from the above-mentioned criteria - users of sour hair rinse - subjects who wash their hair more than once a day - other dermatological disorders (scars, moles) on the scalp - known incompatibilities to cosmetics and ingredients of cosmetic test products (please see INCI) - topical medication in the test area within 1 month prior to study start - systemic medication with anti-inflammatory agents and antibiotics within 2 weeks prior to starting of the study - systemic medication with retinoids, antihistamines and/or immunomodulators (e.g. cortisone, corticosterone, chemotherapeutic agents) within 4 weeks prior to starting of the study - systemic illness of the subject at the beginning of the study - pregnancy and period of breastfeeding |
Country | Name | City | State |
---|---|---|---|
Germany | SIT Skin Investigation and Technology Hamburg GmbH | Hamburg |
Lead Sponsor | Collaborator |
---|---|
Dr. August Wolff GmbH & Co. KG Arzneimittel | Skin Investigation and Technology Hamburg GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tolerance of the Test Product on the Scalp | Change from Baseline Tolerance on the Scalp at 4 weeks | after 4 weeks of treatment | |
Secondary | Skin Hydration of the Scalp | The measurement is performed using the DermaLab® device with the moisture pin (Cortex Technology) | before product treatment; after 2 and 4 weeks of treatment | |
Secondary | Performance of the Test Product | Subjective assessment of product performance in a questionnaire-based interview | after 4 weeks of treatment | |
Secondary | Tolerance of the Test Product on the Scalp | Dermatological assessment of the Scalp concerning the Tolerance of the Test Product regarding erythema, edema dryness etc. Each item is scored 0=absent to 4=extreme. | after 2 weeks of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Terminated |
NCT04086121 -
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
|
Phase 2 | |
Recruiting |
NCT04011215 -
Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)
|
N/A | |
Completed |
NCT04635072 -
Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis
|
Early Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT01945086 -
A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT00541255 -
A Long-Term Examination of Asthma From Childhood Through Adolescence
|
||
Terminated |
NCT04990440 -
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02900131 -
Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients
|
Phase 2 | |
Completed |
NCT03568136 -
Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT03672383 -
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)
|
N/A | |
Completed |
NCT03634345 -
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
|
Phase 1 | |
Enrolling by invitation |
NCT04761978 -
Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
|
||
Completed |
NCT03663673 -
Effect of Different Skin Creams on TEWL
|
Phase 1 | |
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Completed |
NCT02637206 -
Skin Irritation Study of GSK2894512 Cream
|
Phase 1 | |
Completed |
NCT05544591 -
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT05094700 -
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
|
N/A |